CD101: a novel long-acting echinocandin
Open accessAbstract
CD101 is a novel echinocandin drug being developed to treat severe fungal infections including invasive candidiasis. We have performed a series of studies to evaluate the antifungal properties of CD101 against both echinocandin-susceptible and -resistant Candida strains. Antifungal susceptibility testing performed on a collection of 95 Candida strains including 30 caspofungin-resistant isolates containing fks mutations demonstrated comparable antifungal potency of CD101 relative to micafungin (MCF) across different Candida species. Comparable kinetic inhibition of glucan synthase activity was also observed for CD101 and MCF on both wild-type (WT) and resistant fks mutant Candida strains. Similarly, both drugs yielded nearly identical values for a mutant prevention concentration. In a murine model of invasive candidiasis, CD101 displayed better or at least comparable efficacy relative to MCF in treating WT or fks mutant Candida albicans. An exceptional long-lived pharmacokinetic profile was observed in mice following a single dose of CD101. Collectively, CD101 has great potential not only in treating invasive Candida infections but also in preventing emergence of resistance to currently approved echinocandin drugs.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Rezafungin is a new long-acting echinocandin with improved stability and extended half-life compared to first-generation echinocandins, potentially allowing once-a-week dosing.
“Rezafungin (formerly CD101) is a new long-acting echinocandin with improved stability and extended half life as compared to the first generation drugs within this class, thereby potentially allowing for once a week dosing [41].”
From Antifungal therapy of Candida biofilms: Past, present and future (2023) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · see citing works
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · see citing works
How to calculate sample size in animal studies?
Charan, J., & Kantharia, N. D. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.119726 · Cited by 1,881 · see citing works
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298 · see citing works
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · see citing works
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · see citing works
Self-citationParczewska, O. K., Posaconazol, przeciwgrzybicze, L., Anidulafungina, Micafungina, & wrażliwość, O. (2009) · Cited by 656 · see citing works
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434 · see citing works
Self-citationZhao, X., & Drlica, K. (2001) · Clinical Infectious Diseases · doi:10.1086/321841 · Cited by 397 · see citing works
Mutant Selection Window Hypothesis Updated
Drlica, K., & Zhao, X. (2007) · Clinical Infectious Diseases · doi:10.1086/511642 · Cited by 385 · see citing works
Lortholary, O., Desnos-Ollivier, M., Sitbon, K., Fontanet, A., Bretagne, S., & Dromer, F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01128-10 · Cited by 362 · see citing works
Douglas, C. M., D'Ippolito, J. A., Shei, G.-J., Meinz, M., Onishi, J. C., Marrinan, J. A., Li, W., Abruzzo, G. K., Flattery, A. M., Bartizal, K. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2471 · Cited by 344 · see citing works
Self-citationDiscovery of Novel Antifungal (1,3)-β- d -Glucan Synthase Inhibitors
Onishi, J. C., Meinz, M., Thompson, J. R., Curotto, J. E., Dreikorn, S., Rosenbach, M. J., Douglas, C. M., Abruzzo, G. K., Flattery, A. M., Kong, L., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.368-377.2000 · Cited by 326 · see citing works
Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323 · see citing works
Self-citationEchinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299 · see citing works
Self-citationDong, Y., Zhao, X., Domagala, J. M., & Drlica, K. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1756 · Cited by 278 · see citing works
Current Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274 · see citing works
Self-citationIn Vivo Postantibiotic Effect in a Thigh Infection in Neutropenic Mice
Vogelman, B., Gudmundsson, S. R., Turnidge, J. D., Leggett, J., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/157.2.287 · Cited by 257 · see citing works
Compounds active against cell walls of medically important fungi
Hector, R. F. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.1.1 · Cited by 242 · see citing works
Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., & Castanheira, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01079-10 · Cited by 238 · see citing works
Pfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N., & Castanheira, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00308-13 · Cited by 237 · see citing works
FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Beyda, N. D., John, J., Kilic, A., Alam, M. J., Lasco, T. M., & Garey, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu407 · Cited by 174 · see citing works
Update on Antifungal Drug Resistance
Perlin, D. S., Shor, E., & Zhao, Y. (2015) · Current Clinical Microbiology Reports · doi:10.1007/s40588-015-0015-1 · Cited by 174 · see citing works
Self-citationShields, R. K., Nguyen, M. H., Press, E. G., Kwa, A. L., Cheng, S., Du, C., & Clancy, C. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00027-12 · Cited by 171 · see citing works
Castanheira, M., Woosley, L. N., Diekema, D. J., Messer, S. A., Jones, R. N., & Pfaller, M. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01711-09 · Cited by 125 · see citing works
Olofsson, S. K. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl135 · Cited by 124 · see citing works
The postantibiotic effect of antifungal agents against common pathogenic yeasts
Turnidge, J. D., Gudmundsson, S., Vogelman, B., & Craig, W. A. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/34.1.83 · Cited by 105 · see citing works
Firsov, A. A., Smirnova, M. V., Lubenko, I. Y., et al. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl387 · Cited by 95 · see citing works
A unified anti-mutant dosing strategy
Zhao, X., & Drlica, K. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn229 · Cited by 75 · see citing works
Fekkar, A., Dannaoui, É., Meyer, I., Imbert, S., Brossas, J., Uzunov, M., Mellon, G., Nguyen‐Quoc, S., Guiller, E., Caumes, É., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2096-9 · Cited by 63 · see citing works
Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans
Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R., & Patterson, T. F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01750-10 · Cited by 61 · see citing works
Croisier, D., Etienne, M., Piroth, L., et al. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh393 · Cited by 50 · see citing works
Etienne, M., Croisier, D., Charles, P., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/423853 · Cited by 43 · see citing works
Use of an Animal Model of Disseminated Candidiasis in the Evaluation of Antifungal Therapy
Andes, D. R. (2005) · Humana Press eBooks · doi:10.1385/1-59259-943-5:111 · Cited by 28 · see citing works
Castanheira, M., Messer, S., Rhomberg, P., Jones, R. J., & Pfaller, M. A. (2014) · Cited by 9 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- Ong, V., Hough, G., Schlosser, M., Bartizal, K., Balkovec, J., James, K., Krishnana, R. (2015a) Preclinical evaluation shows CD101, a novel echinocandin, is highly stable with no hepatotoxicity in rats. A‐015. In the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy (ICC) joint meeting. San Diego.
- Ong, V., Miesel, L., Bartizal, K., Huang, H.H., Chien, J.C. (2015b) Prolonged efficacy following one dose of a novel echinocandin, CD101, in a neutropenic mouse model of disseminated candidiasis. F‐761. In the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Society of Chemotherapy (ICC) joint meeting.
- Rubino, C.M., O.V., Thye, D., Ambrose, P.G. (2015) Pharmacokinetics–Pharmacodynamics (PK–PD) of a Novel Echinocandin, CD101 (Biafungin), in a Neutropenic Murine Disseminated Candidiasis Model. Slide Session 044. In the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Society of Chemotherapy (ICC) joint meeting. San Diego.
Cited by
Sorted by citations
Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02324-8 · Cited by 192 · see citing works
Thompson, G. R., Soriano, A., Skoutelis, A., Vazquez, J. A., Honore, P. M., Horcajada, J. P., Spapen, H., Bassetti, M., Ostrosky-Zeichner, L., Das, A. F., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1380 · Cited by 163 · see citing works
Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults
Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161 · see citing works
Self-citationThe antifungal arsenal: alternative drugs and future targets
Wiederhold, N. P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.002 · Cited by 149 · see citing works
Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris
Berkow, E. L., & Lockhart, S. R. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.10.021 · Cited by 110 · see citing works
Zhao, Y., Prideaux, B., Nagasaki, Y., Lee, M. H., Chen, P.-Y., Blanc, L., Ho, H., Clancy, C. J., Nguyen, M. H., Dartois, V., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-17 · Cited by 102 · see citing works
Self-citationIn vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae
Tóth, Z., Forgács, L., Locke, J. B., Kardos, G., Nagy, F., Kovács, R., Szekely, A., Borman, A. M., & Majoros, L. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz390 · Cited by 82 · see citing works
Self-citationRecent Insights into the Paradoxical Effect of Echinocandins
Wagener, J., & Loiko, V. (2017) · Journal of Fungi · doi:10.3390/jof4010005 · Cited by 73 · see citing works
Pfaller, M. A., Carvalhaes, C., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00099-20 · Cited by 68 · see citing works
Rezafungin: a novel antifungal for the treatment of invasive candidiasis
Ham, Y. Y., Lewis, J. S., & Thompson, G. R. (2021) · Future Microbiology · doi:10.2217/fmb-2020-0217 · Cited by 66 · see citing works
Antifungal therapy of Candida biofilms: Past, present and future
Ajetunmobi, O. H., Badali, H., Romo, J. A., Ramage, G., & Lopez-Ribot, J. L. (2023) · Biofilm · doi:10.1016/j.bioflm.2023.100126 · Cited by 52 · see citing works
Chandra, J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01750-17 · Cited by 36 · see citing works
Biofilms and beyond: Expanding echinocandin utility
Larkin, E. L., Dharmaiah, S., & Ghannoum, M. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx451 · Cited by 31 · see citing works
- Authors
- Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S.
- Affiliations
- Rutgers Health (US)
- Cidara Therapeutics (United States) (US)
- Corresponding author
- Perlin, David S.
- ORCID
- Venue
- Cellular Microbiology
- Publisher
- Wiley
- Published
- 2016-07-22
- Volume
- 18
- Issue
- 9
- Pages
- 1308-1316
- ISSN
- 1462-5814 (ISSN-L)
- 1462-5822
- PMC
- PMC5096055
- OpenAlex
- W2467264597
- Cited by
- 81
- References
- 36
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 7 · 2023: 8 · 2022: 5 · 2021: 6 · 2020: 10 · 2019: 10 · 2018: 7 · 2017: 17 · 2016: 3
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cellular Microbiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Cidara Therapeutic, Inc.
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- CD101, echinocandins, invasive candidiasis, Candida albicans, caspofungin resistance, micafungin, antifungal susceptibility, mutant prevention concentration, antifungal drug development
- MeSH terms
- Animals, Antifungal Agents, Candida albicans, Candidiasis, Female, Half-Life, Mice, Inbred BALB C, Microbial Sensitivity Tests, Inhibitory Concentration 50, Drug Resistance, Fungal, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
